Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapansutrile for acute gout flare
2019-002717-19Phase 2Active
- Sponsor
- Olatec Therapeutics LLC
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in gout comparing Dapansutrile with Placebo (2 arms). Primary endpoint: Change from baseline in target joint pain intensity at 72 hours. Started Dec 2022; status: active.
02
Drugs
dapansutrile
03
Conditions
gout
Beyond the preview
Go deeper on 2019-002717-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002717-19.